Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: A randomized, double-blind, placebo-controlled trial

Akira Terano, Tetsuo Arakawa, Toshiro Sugiyama, Hidekazu Suzuki, Takashi Joh, Toshikazu Yoshikawa, Kazuhide Higuchi, Ken Haruma, Kazunari Murakami, Kenzo Kobayashi

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background: One week of Helicobacter pylori eradication therapy is insufficient for healing of gastric ulcers. We examined the efficacy of rebamipide in gastric ulcer healing following 1 week of eradication therapy in a randomized, double-blind, placebo-controlled trial. Methods: Patients with H. pylori-positive gastric ulcer were enrolled and received 1 week of eradication therapy, followed by 100 mg of rebamipide or placebo for 7 weeks. The primary end point was the gastric ulcer healing rate. Results: Of the 309 patients entered in the trial, 301 completed H. pylori eradication therapy; 154 patients took rebamipide, and 147 took placebo. The healing rate in the rebamipide group was higher than that in the placebo group in the per-protocol analysis 80.0% (104/130) versus 66.1% (82/124) [95% confidence interval (CI), 3.1 24.7; P = 0.013) and in a full analysis 70.1% (108/154) versus 60.5% (89/147) (95% CI, 1.1 to 20.3; P = 0.080). Conclusions: Compared with placebo, rebamipide significantly promoted gastric ulcer healing following 1 week of eradication therapy.

Original languageEnglish
Pages (from-to)690-693
Number of pages4
JournalJournal of Gastroenterology
Volume42
Issue number8
DOIs
Publication statusPublished - 2007 Aug

Fingerprint

Stomach Ulcer
Helicobacter pylori
Anti-Inflammatory Agents
Placebos
Pharmaceutical Preparations
Population
Confidence Intervals
Therapeutics
rebamipide

Keywords

  • Clinical trial
  • Eradication
  • Gastric ulcer
  • H. pylori
  • Japanese population
  • Placebo-controlled trial
  • Rebamipide
  • Ulcer healing

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population : A randomized, double-blind, placebo-controlled trial. / Terano, Akira; Arakawa, Tetsuo; Sugiyama, Toshiro; Suzuki, Hidekazu; Joh, Takashi; Yoshikawa, Toshikazu; Higuchi, Kazuhide; Haruma, Ken; Murakami, Kazunari; Kobayashi, Kenzo.

In: Journal of Gastroenterology, Vol. 42, No. 8, 08.2007, p. 690-693.

Research output: Contribution to journalArticle

Terano, Akira ; Arakawa, Tetsuo ; Sugiyama, Toshiro ; Suzuki, Hidekazu ; Joh, Takashi ; Yoshikawa, Toshikazu ; Higuchi, Kazuhide ; Haruma, Ken ; Murakami, Kazunari ; Kobayashi, Kenzo. / Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population : A randomized, double-blind, placebo-controlled trial. In: Journal of Gastroenterology. 2007 ; Vol. 42, No. 8. pp. 690-693.
@article{9842775a36384e849b6236fb571e4fe2,
title = "Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: A randomized, double-blind, placebo-controlled trial",
abstract = "Background: One week of Helicobacter pylori eradication therapy is insufficient for healing of gastric ulcers. We examined the efficacy of rebamipide in gastric ulcer healing following 1 week of eradication therapy in a randomized, double-blind, placebo-controlled trial. Methods: Patients with H. pylori-positive gastric ulcer were enrolled and received 1 week of eradication therapy, followed by 100 mg of rebamipide or placebo for 7 weeks. The primary end point was the gastric ulcer healing rate. Results: Of the 309 patients entered in the trial, 301 completed H. pylori eradication therapy; 154 patients took rebamipide, and 147 took placebo. The healing rate in the rebamipide group was higher than that in the placebo group in the per-protocol analysis 80.0{\%} (104/130) versus 66.1{\%} (82/124) [95{\%} confidence interval (CI), 3.1 24.7; P = 0.013) and in a full analysis 70.1{\%} (108/154) versus 60.5{\%} (89/147) (95{\%} CI, 1.1 to 20.3; P = 0.080). Conclusions: Compared with placebo, rebamipide significantly promoted gastric ulcer healing following 1 week of eradication therapy.",
keywords = "Clinical trial, Eradication, Gastric ulcer, H. pylori, Japanese population, Placebo-controlled trial, Rebamipide, Ulcer healing",
author = "Akira Terano and Tetsuo Arakawa and Toshiro Sugiyama and Hidekazu Suzuki and Takashi Joh and Toshikazu Yoshikawa and Kazuhide Higuchi and Ken Haruma and Kazunari Murakami and Kenzo Kobayashi",
year = "2007",
month = "8",
doi = "10.1007/s00535-007-2076-2",
language = "English",
volume = "42",
pages = "690--693",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "8",

}

TY - JOUR

T1 - Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population

T2 - A randomized, double-blind, placebo-controlled trial

AU - Terano, Akira

AU - Arakawa, Tetsuo

AU - Sugiyama, Toshiro

AU - Suzuki, Hidekazu

AU - Joh, Takashi

AU - Yoshikawa, Toshikazu

AU - Higuchi, Kazuhide

AU - Haruma, Ken

AU - Murakami, Kazunari

AU - Kobayashi, Kenzo

PY - 2007/8

Y1 - 2007/8

N2 - Background: One week of Helicobacter pylori eradication therapy is insufficient for healing of gastric ulcers. We examined the efficacy of rebamipide in gastric ulcer healing following 1 week of eradication therapy in a randomized, double-blind, placebo-controlled trial. Methods: Patients with H. pylori-positive gastric ulcer were enrolled and received 1 week of eradication therapy, followed by 100 mg of rebamipide or placebo for 7 weeks. The primary end point was the gastric ulcer healing rate. Results: Of the 309 patients entered in the trial, 301 completed H. pylori eradication therapy; 154 patients took rebamipide, and 147 took placebo. The healing rate in the rebamipide group was higher than that in the placebo group in the per-protocol analysis 80.0% (104/130) versus 66.1% (82/124) [95% confidence interval (CI), 3.1 24.7; P = 0.013) and in a full analysis 70.1% (108/154) versus 60.5% (89/147) (95% CI, 1.1 to 20.3; P = 0.080). Conclusions: Compared with placebo, rebamipide significantly promoted gastric ulcer healing following 1 week of eradication therapy.

AB - Background: One week of Helicobacter pylori eradication therapy is insufficient for healing of gastric ulcers. We examined the efficacy of rebamipide in gastric ulcer healing following 1 week of eradication therapy in a randomized, double-blind, placebo-controlled trial. Methods: Patients with H. pylori-positive gastric ulcer were enrolled and received 1 week of eradication therapy, followed by 100 mg of rebamipide or placebo for 7 weeks. The primary end point was the gastric ulcer healing rate. Results: Of the 309 patients entered in the trial, 301 completed H. pylori eradication therapy; 154 patients took rebamipide, and 147 took placebo. The healing rate in the rebamipide group was higher than that in the placebo group in the per-protocol analysis 80.0% (104/130) versus 66.1% (82/124) [95% confidence interval (CI), 3.1 24.7; P = 0.013) and in a full analysis 70.1% (108/154) versus 60.5% (89/147) (95% CI, 1.1 to 20.3; P = 0.080). Conclusions: Compared with placebo, rebamipide significantly promoted gastric ulcer healing following 1 week of eradication therapy.

KW - Clinical trial

KW - Eradication

KW - Gastric ulcer

KW - H. pylori

KW - Japanese population

KW - Placebo-controlled trial

KW - Rebamipide

KW - Ulcer healing

UR - http://www.scopus.com/inward/record.url?scp=34548019247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548019247&partnerID=8YFLogxK

U2 - 10.1007/s00535-007-2076-2

DO - 10.1007/s00535-007-2076-2

M3 - Article

C2 - 17701133

AN - SCOPUS:34548019247

VL - 42

SP - 690

EP - 693

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 8

ER -